AOD-9604: the hGH 176-191 fragment studied for fat metabolism

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal end of human growth hormone, residues 176-191. it was developed by Metabolic Pharmaceuticals in Australia in the 1990s as an anti-obesity candidate on the theory that this fragment captured the lipolytic activity of GH without the IGF-1-driven growth signal. the obesity program reached Phase 2 and stopped there for efficacy reasons.

what is AOD-9604?

AOD-9604 is "anti-obesity drug 9604", a synthetic fragment of human growth hormone. the molecule corresponds to residues 176-191 of the 191-amino-acid hGH protein, often written as hGH(176-191) or, with a tyrosine added to the front to stabilize synthesis, hGH(177-191). its more recent research name in immunology and metabolism work is LAT8881.

the rationale for the C-terminal fragment is that, in early animal studies, the lipolytic and metabolic effects of growth hormone seemed to map to a region near the back of the molecule rather than to the front, which carries the GH-receptor-binding face. if that mapping was correct, then a short peptide from the C-terminus could in principle deliver the fat-burning effect of GH without driving the IGF-1 elevation that accompanies full-length GH therapy. AOD-9604 was the lead candidate that came out of that program.

the more recent literature uses the LAT8881 name. Harpur and colleagues in Clinical & Translational Immunology in 2023 describe LAT8881 as "a synthetic form of the C-terminal fragment of human growth hormone" and note that it "(formerly identified as AOD9604)" operates through LANCL family proteins rather than through the GH receptor itself [1]. that paper, focused on viral infection rather than obesity, is part of the slow repositioning of the molecule away from a pure fat-loss story.

how is it proposed to work?

AOD-9604 cannot bind the growth hormone receptor because it lacks the part of the GH molecule that does that binding. the proposed mechanism instead involves receptor-independent stimulation of lipolysis in adipocytes and, in more recent work, signaling through the LANCL family of intracellular proteins. the GH-receptor independence is the property that, in the original commercial pitch, separated AOD-9604 from full recombinant human growth hormone.

in classical preclinical work, GH-deficient and obese-rodent models given the hGH C-terminal fragment showed increased fat oxidation and reduced fat mass without the IGF-1 elevation or insulin resistance associated with full-length GH. the molecular pathway behind that effect has been incompletely characterized for most of AOD-9604's history, which is why it has typically been described in trade press as having an "unknown receptor".

the LANCL-protein hypothesis from the Harpur paper is the cleanest mechanistic proposal published in a peer-reviewed venue [1]. in that work the LAT8881 form of the peptide engages intracellular LANCL proteins to modulate immune and metabolic responses during influenza infection in mice, with measurable reduction in viral replication and tissue damage. the broader implication is that the "hGH C-terminal fragment" family of peptides may work through a previously underappreciated intracellular pathway rather than any classical cell-surface receptor.

what does the evidence show?

the largest body of human evidence is the Metabolic Pharmaceuticals obesity program of the 2000s, which advanced to a 24-week Phase 2 trial. published Phase 2 results did not show meaningful weight loss versus placebo at the doses tested, and the program was discontinued for the obesity indication. there are no large randomized Phase 3 trials in any population.

a 2026 review by Rahman and colleagues in Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews summarizes AOD-9604 as a peptide that "promotes fat metabolism and may support cartilage repair without markedly altering glucose homeostasis or systemic IGF-1 levels" [2]. the same review cites a preclinical rabbit osteoarthritis model in which intra-articular injection of AOD-9604 combined with hyaluronic acid improved cartilage morphology, which is the basis for the molecule's growing use in orthopedic compounding rather than weight loss.

a smaller adjacent literature has examined the hGH 176-191 sequence in cancer biology. Habibullah and colleagues in Drug Design, Development and Therapy in 2022 reported that loading the C-terminal hGH 176-191 peptide together with doxorubicin into chitosan nanoparticles enhanced toxicity against MCF-7 breast cancer cells in vitro [3]. that is a delivery-system finding, not an AOD-9604 efficacy claim, but it confirms that the fragment retains measurable biological activity in modern hands.

outside those datasets the published controlled evidence on AOD-9604 specifically is thin. most online claims about it derive from one of two sources: animal data from the original Metabolic Pharmaceuticals program (largely unpublished in full form), or extrapolation from the well-characterized lipolytic effect of full-length growth hormone. the honest framing is that AOD-9604 has plausible mechanistic logic, a small but real published trail, and no controlled human evidence of meaningful weight loss.

regulatory and research status

AOD-9604 has no FDA approval for any indication. Metabolic Pharmaceuticals secured Generally Recognized as Safe (GRAS) self-affirmation for AOD-9604 as a food ingredient in the late 2000s, but GRAS status is not FDA approval as a drug and does not validate any therapeutic claim. it is currently sold as a research-use-only peptide and listed in compounded orthopedic and weight-loss formulations.

the FDA's 2023 list of bulk substances not eligible for inclusion in compounded products under section 503A and 503B made the regulatory status sharper for compounding pharmacies. AOD-9604 is on the version of that list that compounding pharmacies in the US are increasingly required to honor, which has changed availability over the past two years.

AOD-9604 is on the World Anti-Doping Agency prohibited list under category S2 (peptide hormones, growth factors, related substances and mimetics) at all times. any competitive athlete in a WADA-tested sport should be aware that use is banned in and out of competition.

safety considerations

the published short-term safety profile from the Phase 2 obesity program was unremarkable, with no major treatment-emergent adverse events at the doses tested. long-term safety in healthy adults using compounded research-peptide formulations has not been characterized, and the modern LANCL-pathway data does not yet address the chronic-use safety question in any peer-reviewed venue.

because AOD-9604 does not engage the GH receptor, it does not produce the IGF-1 elevation that drives many of the side effects of full-length growth hormone therapy. in the published preclinical and small clinical work it has not been associated with the joint aches, fluid retention, or fasting-glucose shifts that come up in tesamorelin and other GH-axis tools. whether that clean profile holds at multi-year exposures and at the higher milligram amounts sometimes used in compounding is not known.

as with any peptide sold as research-use only, manufacturing variability and contamination are practical concerns that the published efficacy literature cannot address. the consumer-facing "weight loss peptide" framing of AOD-9604 has run far ahead of any controlled human evidence supporting that claim, which is the single most important point a beginner should take from this page.

where it fits in peptide research

AOD-9604 is a single point in a much larger landscape of fat-loss-targeted peptide research. its closest neighbors are full-length growth hormone, the GHRH analog tesamorelin, and the GLP-1 family. each of those touches body composition through a different mechanism, and only tesamorelin and the GLP-1 family have controlled human evidence of meaningful effect.

the natural comparison is with tesamorelin, which acts upstream through the GHRH receptor to amplify natural GH pulses and is FDA-approved for HIV-associated visceral fat reduction with Phase 3 evidence. AOD-9604 sits on the other extreme: a small fragment that bypasses the GH axis entirely but lacks Phase 3 efficacy data. readers comparing the two should weight the evidence base, not just the mechanism.

for a broader map of how peptides reshape fat distribution, the GLP-1 comparison guide covers the metabolic axis that has actually produced large weight-loss effects in randomized trials, and the vetting research peptides guide covers how to evaluate any compound sold under a research-use-only label. for the underlying biology of how peptides interact with receptors and feedback loops, see the free peptides and your body module.